XXXXXXX XXXXXXXXXXXX. Xxxxxx Xxxxxx
XXXXXXX XXXXXXXXXXXX. The Chargor shall
XXXXXXX XXXXXXXXXXXX. Xxx Xxxxxx xxxxx xxx xx xxx Company on or before the Effective Date a Capital Contribution of $1,000.
XXXXXXX XXXXXXXXXXXX. Xxxxxxx Xxxxxxxxxxxx" xxall mean any contribution to the capital of the Company in cash or property by a Member whenever made, including without limitation any payments made by a Member in satisfaction of any obligation of the Company.
XXXXXXX XXXXXXXXXXXX. For the Republic of Bosnia and Herzegovina Declaration On Behalf Of The Federation Of Bosnia And Herzegovina The Federation of Bosnia and Herzegovina, on behalf of its constituent peoples and citizens, approves the Constitution of Bosnia and Herzegovina at Annex 4 to the General Framework Agreement.
XXXXXXX XXXXXXXXXXXX. H The energetic Xxxxxxx Xxxxxxxxxxxx has much on his agenda as director of the Research Institute of the XxXxxx University Health Centre, but that will not keep him from his own research activities. is lab activities focus on understanding the mecha- nisms underlying the body’s production of steroids, a field with wide-ranging therapeutic possibilities. “Steroids are fundamental. We can trace them to the Precambrian period 500 million years ago, and have found them in plants, insects and humans,” he explains. “They are so basic that every time steroid levels change, the impact is evident.” As a result, he says, “while we are investigating something very focused – how steroids are made in the body – the information we discover immediately applies to different diseases.” For instance, pathologies such as cancer, infertility and Alzheimer’s often exhibit levels of steroid production that are abnormally high or low. “So learning about steroid- production mechanisms also helps us to develop drugs that address the metabolic errors that contribute to these diseases,” he explains. Because many of his discoveries have therapeutic potential, Xxxxxxxxxxxx holds numerous scientific patents and has also served as a consultant to pharmaceutical and biotechnology companies. These experiences have come in handy when establishing Montreal Excellerator. “Xxxxxxx is a master of commercialization,” says Xxxxx Xxxxxxx, XxXxxx’x vice-prin- cipal (Research and International Relations), “and he really sped up the company’s creation.” A native of Greece, Xxxxxxxxxxxx received his first degree in pharmacy from the University of Athens, earned his PhD from the Université Pierre & Xxxxx Xxxxx in Paris, and worked as a post-doctoral fellow in France and Australia. He then joined Georgetown University in Washington, D.C., in 1988, where he served as chair of Biochemistry and Molecular Biology and associate vice-president of research for the university’s Medical Center. In 2007, he moved to McGill with his wife Xxxxxxx Xxxxx, a specialist in the biology of testicular germ cells and an associ- ate professor in the Faculty of Medicine. “I now have five different social insurance numbers,” he jokes. Fortunately, it was not a difficult decision to add the most recent one. “Choosing to come to McGill was easy – it’s a truly international community with an outstanding reputation,” he says. “And in life you only have so many opportunities to really help build something as big as what we are do...
XXXXXXX XXXXXXXXXXXX. By: Xxx Xxxxx AVP, Global Capital Excellence and Engineering Leader and Authorized Representative STATE OF IOWA ) ) SS COUNTY OF LINN ) On this day of , 2019, before me a Notary Public in and for said County, Xxx Xxxxx personally appeared and to me personally known, who being duly sworn, did say he is AVP of Xxxxxxx, Xxxxxxxxxxxx., created and existing under the laws of the State of Iowa, and that said instrument was signed on behalf of said Limited Liability Company and acknowledged said instrument to be the free act and deed of said Liability Company by it voluntarily executed. Notary Public in and for Linn County, Iowa
XXXXXXX XXXXXXXXXXXX. Xxxxxx Xxxxxx Each Underwriter severally represents and agrees that it will not offer or sell the Securities in the United States or to United States persons except if such offers or sales are made by or through broker-dealers registered with the U.S. Securities and Exchange Commission. Australia No Final Prospectus, Basic Prospectus, or any other disclosure document in relation to the Capital Securities has been or will be lodged with the Australian Securities and Investment Commission ("ASIC"). Each of the Underwriters represents and agrees that it:
XXXXXXX XXXXXXXXXXXX xxx. The Private Collector shall remit to the City each month a fee calculated by multiplying the rate per cubic yard set forth in City Code Section 27-557(a)(6) (i.e., $2.07 as of October 1, 2023). For example, the fee as of October 1, 2023 will be calculated as follows:
XXXXXXX XXXXXXXXXXXX. Xxxxx Xxxxxx Prior to the issue of any Tranche of Notes under the Programme, each Dealer has (or will have) represented, warranted and agreed that it (i) will not offer Notes for subscription, (ii) will not solicit any offers for subscription for or sale of the Notes, and (iii) will itself not sell or offer the Notes in South Africa in contravention of the Companies Act, Banks Act, Exchange Control Regulations and/or any other Applicable Laws and regulations of South Africa in force from time to time. Prior to the issue of any Tranche of Notes under the Programme, each Dealer who has (or will have) agreed to place that Tranche of Notes will be required to represent and agree that it will not make an “offer to the public” (as such expression is defined in the Companies Act, and which expression includes any section of the public) of Notes (whether for subscription, purchase or sale) in South Africa. This Agreement does not, nor is it intended to, constitute a prospectus prepared and registered under the Companies Act. Offers not deemed to be offers to the public As at the date of this Agreement, an offer for subscription for, or sale of, Notes are not deemed to be offers to the public if: made to certain investors contemplated in section 96(1)(a) of the Companies Act; or the total contemplated acquisition cost of Notes, for any single addressee acting as principal, shall be equal to or greater than ZAR1,000,000, or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the Companies Act. Information made available in this Agreement should not be considered as “advice” as defined in the Financial Advisory and Intermediary Services Act, 2002. United States The Notes have not been and will not be registered under the Securities Act and may not be offered or sold within the United States or to, or for the account of or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the Securities Act. Terms used in this paragraph have the meanings given to them by Regulation S under the Securities Act. Prior to the issue of any Tranche of Notes under the Programme, any Dealer who has (or will have) agreed to place that Tranche of Notes will be required to represent and agree that: the Notes in that Tranche have not been and will not be registered under the Securities Act and may not be offered or sold within the United States or to, or for the account of o...
